213 related articles for article (PubMed ID: 28296726)
21. Complexed and total PSA in patients with benign prostatic hyperplasia and prostate cancer.
Tamimi W; Dafterdar R; Mansi M; Alsaad K; Alarifi SA
Br J Biomed Sci; 2010; 67(4):184-8. PubMed ID: 21294445
[TBL] [Abstract][Full Text] [Related]
22. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
Horninger W; Cheli CD; Babaian RJ; Fritsche HA; Lepor H; Taneja SS; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Bartsch G
Urology; 2002 Oct; 60(4 Suppl 1):31-5. PubMed ID: 12384160
[TBL] [Abstract][Full Text] [Related]
23. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA.
Parsons JK; Brawer MK; Cheli CD; Partin AW; Djavan R
BJU Int; 2004 Jul; 94(1):47-50. PubMed ID: 15217429
[TBL] [Abstract][Full Text] [Related]
24. [Usefulness of PSA and its fractions in the diagnosis of prostate cancer].
Filella X; Truan D; Alcover J; Molina R; Luque P; Coca F; Ballesta AM
Med Clin (Barc); 2004 Feb; 122(7):241-4. PubMed ID: 15012870
[TBL] [Abstract][Full Text] [Related]
25. Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis.
Taneja SS; Hsu EI; Cheli CD; Walden P; Bartsch G; Horninger W; Babaian RJ; Fritsche HA; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Lepor H
Urology; 2002 Oct; 60(4 Suppl 1):10-7. PubMed ID: 12384157
[TBL] [Abstract][Full Text] [Related]
26. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
[TBL] [Abstract][Full Text] [Related]
27. Prostate Cancer Predictive Simulation Modelling, Assessing the Risk Technique (PCP-SMART): Introduction and Initial Clinical Efficacy Evaluation Data Presentation of a Simple Novel Mathematical Simulation Modelling Method, Devised to Predict the Outcome of Prostate Biopsy on an Individual Basis.
Spyropoulos E; Kotsiris D; Spyropoulos K; Panagopoulos A; Galanakis I; Mavrikos S
Clin Genitourin Cancer; 2017 Feb; 15(1):129-138.e1. PubMed ID: 27460552
[TBL] [Abstract][Full Text] [Related]
28. Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
Strittmatter F; Stieber P; Nagel D; Füllhase C; Walther S; Stief CG; Waidelich R
Eur J Med Res; 2011 Oct; 16(10):445-50. PubMed ID: 22024423
[TBL] [Abstract][Full Text] [Related]
29. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
Gao ZW; Liu G; Sheng BW
Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
[TBL] [Abstract][Full Text] [Related]
30. Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy.
Wesseling S; Stephan C; Semjonow A; Lein M; Brux B; Sinha P; Loening SA; Jung K
Clin Chem; 2003 Jun; 49(6 Pt 1):887-94. PubMed ID: 12765984
[TBL] [Abstract][Full Text] [Related]
31. [Comparative value of molecular forms of prostate-specific antigen in diagnosis of prostatic cancer].
Mazo EB; Sergeeva NA; Grigor'ev ME; Lebedev DV; Solov'eva EV; Konorev VA; Krovets AA
Urologiia; 2006; (3):21-4. PubMed ID: 16889084
[TBL] [Abstract][Full Text] [Related]
32. [Measurement and analysis of different serum PSA in patients with benign prostatic hyperplasia].
Li Y; Xu P; Zhang PA; Su HW; Zhang J
Zhonghua Nan Ke Xue; 2003 Aug; 9(5):361-3, 366. PubMed ID: 14513646
[TBL] [Abstract][Full Text] [Related]
33. Elevated prostate specific antigen and reduced 10-year survival among a cohort of Danish men consecutively referred from primary care to an urological department during 2005-2006.
Hillig T; Nielsen TK; Hansen SI; Nygaard AB; Sölétormos G
Scand J Clin Lab Invest; 2017 Feb; 77(1):27-35. PubMed ID: 27762145
[TBL] [Abstract][Full Text] [Related]
34. Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer.
Zhang WM; Finne P; Leinonen J; Salo J; Stenman UH
Urology; 2000 Aug; 56(2):267-72. PubMed ID: 10925092
[TBL] [Abstract][Full Text] [Related]
35. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
Stephan C; Cammann H; Deger S; Schrader M; Meyer HA; Miller K; Lein M; Jung K
Urology; 2009 Oct; 74(4):873-7. PubMed ID: 19476981
[TBL] [Abstract][Full Text] [Related]
36. Complexed PSA in routine diagnosis.
Oremek GM; Sapoutzis N; Eden F; Jonas D
Anticancer Res; 2003; 23(2A):975-7. PubMed ID: 12820333
[TBL] [Abstract][Full Text] [Related]
37. [Diagnostic value of complexed prostate-specific antigen for prostate cancer].
Su HW; Li Y; Xu P
Zhonghua Nan Ke Xue; 2003 Sep; 9(6):431-3. PubMed ID: 14574807
[TBL] [Abstract][Full Text] [Related]
38. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
[TBL] [Abstract][Full Text] [Related]
39. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
Urology; 2000 May; 55(5):694-9. PubMed ID: 10792083
[TBL] [Abstract][Full Text] [Related]
40. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]